ArticleJournal of clinical microbiology2000
Serodiagnosis of Louse-Borne relapsing fever with glycerophosphodiester phosphodiesterase (GlpQ) from Borrelia recurrentis.
Article in Journal of clinical microbiology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.
- Louse-borne relapsing fever-A systematic review and analysis of the literature: Part 1-Epidemiology and diagnostic aspects.PLoS neglected tropical diseases · 2021Pooled it
- Relapsing fever revisited: New insights into neglected borrelial infections.PLoS neglected tropical diseases · 2026Review
- Serological Analysis Indicating the Exposure of Two Volunteers to Relapsing Fever Borrelia sp. in Nayarit, Mexico.The American journal of tropical medicine and hygiene · 2025Article
- Characterization of Immunological Responses toMicrobiology spectrum · 2022Article
- Novel approaches for the serodiagnosis of louse-borne relapsing fever.Frontiers in cellular and infection microbiology · 2022Article
- Pathogenesis of Relapsing Fever.Current issues in molecular biology · 2021Review
- Glycerophosphodiester Phosphodiesterase Identified as Non-Reliable Serological Marker forMicroorganisms · 2020Article
- Line Immunoblot Assay for Tick-Borne Relapsing Fever and Findings in Patient Sera from Australia, Ukraine and the USA.Healthcare (Basel, Switzerland) · 2019Article
- Testing the Competence ofThe American journal of tropical medicine and hygiene · 2019Article
- Case report: A retrospective serological analysis indicating human exposure to tick-borne relapsing fever spirochetes in Sonora, Mexico.PLoS neglected tropical diseases · 2019Article
- Louse-borne relapsing fever (Borrelia recurrentis infection).Epidemiology and infection · 2019Review
- Seroprevalence for the tick-borne relapsing fever spirochete Borrelia turicatae among small and medium sized mammals of Texas.PLoS neglected tropical diseases · 2018Article
- First insights in the variability of Borrelia recurrentis genomes.PLoS neglected tropical diseases · 2017Article
- Article
- Tick-Borne Relapsing Fever Spirochetes in the Americas.Veterinary sciences · 2016Article
- Vaccination with the variable tick protein of the relapsing fever spirochete Borrelia hermsii protects mice from infection by tick-bite.Parasites & vectors · 2015Article
- Neglected bacterial zoonoses.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2015Review
- Case report: A retrospective serological analysis indicating human exposure to tick-borne relapsing fever spirochetes in Texas.PLoS neglected tropical diseases · 2015Article
- Laboratory Diagnosis of Tick-Borne African Relapsing Fevers: Latest Developments.Frontiers in public health · 2015Review
- High seroprevalence of Borrelia miyamotoi antibodies in forestry workers and individuals suspected of human granulocytic anaplasmosis in the Netherlands.New microbes and new infections · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
Human louse-borne relapsing fever occurs in sporadic outbreaks in central and eastern Africa that are characterized by significant morbidity and mortality. Isolates of the causative agent, Borrelia recurrentis, were obtained from the blood of four patients during a recent epidemic of the disease in southern Sudan. The glpQ gene, encoding glycerophosphodiester phosphodiesterase, from these isolates was sequenced and compared with the glpQ sequences obtained from other relapsing-fever spirochetes. Previously we showed that GlpQ of Borrelia hermsii is an immunogenic protein with utility as a serological test antigen for discriminating tick-borne relapsing fever from Lyme disease. In the present work, we cloned and expressed the glpQ gene from B. recurrentis and used recombinant GlpQ in serological tests. Acute- and convalescent-phase serum samples obtained from 42 patients with louse-borne relapsing fever were tested with an indirect immunofluorescence assay (IFA) and an enzyme-linked immunosorbent assay (ELISA) that used whole cells of B. recurrentis and with immunoblotting to whole-cell lysates of the spirochete and Escherichia coli producing recombinant GlpQ. The geometric mean titers of the acute- and convalescent-phase serum samples measured by IFA were 1:83 and 1:575, respectively. The immunoblot analysis identified a high level of reactivity and seroconversion to GlpQ, and the assay was more sensitive than the whole-cell IFA and ELISA using purified, recombinant histidine-tagged GlpQ. Serum antibodies to GlpQ and other antigens persisted for 27 years in one patient. We conclude that assessment of anti-GlpQ antibodies will allow serological confirmation of louse-borne relapsing fever and determination of disease prevalence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.